Clinical trials: Proof of Concept
Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography…
- Trial name
- NEON-NPDR (NCT04722991)
- Testing
- Runcaciguat (BAY1101042)
- Where
- 55 sites in United States, Bulgaria and 12 more
- Volunteers
- 109 people
- Sponsor
- Bayer
Diabetic Foot Ulcer
A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers
The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer).
- Trial name
- DFU (NCT06852976)
- Testing
- 0.75% MDI-1228_mesylate gel plus Standard of Care, Standard of Care Alone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
Photosensitive Epilepsy
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
- Trial name
- NCT00784212
- Testing
- BGG492
- Where
- 4 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Obesity & Overweight
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general.
- Trial name
- NCT07728383
- Testing
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Gila Therapeutics, Inc.
Diarrhea
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
The main objective of this study will be to obtain data on the efficacy of elsiglutide in preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving 5-FU based chemotherapy (FOLFOX4 or FOLFIRI…
- Trial name
- NCT01543451
- Testing
- Elsiglutide
- Where
- 21 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 138 people
- Sponsor
- Helsinn Healthcare SA
Obesity
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers.
- Trial name
- NCT06804603
- Testing
- Tradipitant
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Vanda Pharmaceuticals
Fragile X Syndrome
Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients
This study will evaluate the safety, tolerability and efficacy of multiple doses of AFQ056 in patients with Fragile X Syndrome. The dose range will be 50 to 150 mg b.i.d.
- Trial name
- NCT00718341
- Testing
- AF056
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 30 people
- Sponsor
- Novartis
Covid19
Canine COVID-19 Detection
Dogs are some of nature's greatest detectives, owing to their incredible sense of smell and ability to be trained. Most of us will be familiar with seeing trained sniffer dogs at airports looking for drugs and other prohibited…
- Trial name
- NCT04509713
- Testing
- Collection of odour samples
- Where
- United Kingdom
- Volunteers
- 16,250 people, healthy volunteers welcome
- Sponsor
- ARCTEC
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
- Trial name
- NCT03053102
- Testing
- Danicopan
- Where
- 5 sites in Italy, New Zealand and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hot Flashes
FP-101 for the Treatment of Hot Flashes in Postmenopausal Women
The purpose of the study is to determine the efficacy of FP-101 versus placebo for the treatment of hot flashes in postmenopausal women.
- Trial name
- NCT03285672
- Testing
- FP-101
- Where
- 12 sites in United States
- Volunteers
- 109 people
- Sponsor
- Fervent Pharmaceuticals
Asthma in Children
Proof-of-concept of the Measurement of Lung Function Using the Relaxed Expiratory Occlusion Monitor (REOM)
(i) To validate the inversed occlusion technique by comparing the results of resistance obtained on the relaxed expiratory occlusion monitor (REOM) with the resistance obtained with respiratory oscillometry (OSC) measurements on…
- Trial name
- NCT04903145
- Testing
- REOM
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Thorasys Thoracic Medical Systems Inc.
Alzheimer's Disease
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with…
- Trial name
- NCT02580305
- Testing
- SUVN-502, Donepezil, Memantine
- Where
- 71 sites in United States
- Volunteers
- 564 people
- Sponsor
- Suven Life Sciences Limited
Overactive Bladder Syndrome (OABS)
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom…
- Trial name
- NCT00409539
- Testing
- SMP-986
- Where
- 69 sites in United States, Estonia and 7 more
- Volunteers
- 550 people
- Sponsor
- Sumitomo Pharma America, Inc.
Back Pain, Lower Back Pain
Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain
The study includes back pain of the cervical, thoracic, and the lumbar regions.
- Conditions
- Back Pain, Lower Back Pain, Cervical Pain
- Trial name
- NCT01415895
- Testing
- Naltrexone and Clonidine Combination
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Annette C. Toledano MD
Critical Illness, Mechanical Ventilation
Proof of Concept Trial to Confirm That the Recovery of Patients Treated in the Intensive Care Unit Requiring Mechanical Ventilation is Beneficially Affected by the Environmental Simulation of Daytime and Night Time Alternation as Well as by the Nutrition Protocol Corresponding to the Daily Rhythm
The purpose of this study is to determine whether the environmental simulation of daytime and night time alternation as well as by the nutrition protocol corresponding to the daily rhythm are beneficially affect the recovery of…
- Trial name
- NCT02828722
- Testing
- Controlled light and noise, Controlled nutrition
- Where
- Hungary
- Volunteers
- 45 people
- Sponsor
- Achros Health Technologies Corporation
Chronic Kidney Diseases
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
- Trial name
- NCT04990427
- Testing
- CLBS201
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Lisata Therapeutics, Inc.
Hypoglycemia, Complications of Bariatric Procedures
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe…
- Trial name
- NCT02733588
- Testing
- G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xeris Pharmaceuticals
Dry Eye Disease
Phase 2b Controlled Study
Double-masked two period controlled trial of three eyelid wipe dosing techniques
- Trial name
- NCT07140380
- Testing
- IVW-1001 Ophthalmic Eyelid Wipe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- IVIEW Therapeutics Inc.
Bowel Preparation
Safety and Tolerability Study of an Edible Colon Preparation
The purpose of this study is to learn about a new bowel preparation that uses food to clean the colon. In order to learn about this new food preparation, some people in this study will get the food preparation, and others will…
- Trial name
- NCT02402270
- Testing
- NuLYTELY® (PEG 3350), ECP-019, MoviPrep® (PEG 3350)
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- ColonaryConcepts LLC